NASDAQ:BBNX Beta Bionics (BBNX) Stock Price, News & Analysis $18.04 +0.59 (+3.38%) As of 02:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Beta Bionics Stock (NASDAQ:BBNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Beta Bionics alerts:Sign Up Key Stats Today's Range$17.43▼$18.5050-Day Range$12.53▼$18.2352-Week Range$8.89▼$24.50Volume203,713 shsAverage Volume528,925 shsMarket Capitalization$784.20 millionP/E RatioN/ADividend YieldN/APrice Target$22.56Consensus RatingModerate Buy Company Overview Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA. Read More Receive BBNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address BBNX Stock News HeadlinesStephen Feider Sells 5,587 Shares of Beta Bionics (NASDAQ:BBNX) StockAugust 21, 2025 | insidertrades.comBeta Bionics, Inc. to Present at Upcoming Healthcare Investor Conferences in September 2025August 21, 2025 | quiverquant.comQMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 26 at 2:00 AM | American Alternative (Ad)Beta Bionics Announces Participation at Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comBeta Bionics, Inc. (NASDAQ:BBNX) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 18, 2025 | americanbankingnews.comBeta Bionics Reports Record Growth in Earnings CallAugust 1, 2025 | msn.comBeta Bionics, Inc. (BBNX) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comBeta Bionics, Inc. 2025 Q2 - Results - Earnings Call PresentationJuly 31, 2025 | seekingalpha.comSee More Headlines BBNX Stock Analysis - Frequently Asked Questions How have BBNX shares performed this year? Beta Bionics' stock was trading at $23.81 at the beginning of 2025. Since then, BBNX stock has decreased by 24.6% and is now trading at $17.96. How were Beta Bionics' earnings last quarter? Beta Bionics, Inc. (NASDAQ:BBNX) announced its earnings results on Tuesday, July, 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.12. The company had revenue of $23.24 million for the quarter, compared to analyst estimates of $19.73 million. Read the conference call transcript. When did Beta Bionics IPO? Beta Bionics (BBNX) raised $204 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $17.00 per share. When did the company's lock-up period expire? Beta Bionics's lock-up period expired on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its IPO on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period. Who are Beta Bionics' major shareholders? Beta Bionics' top institutional investors include Eventide Asset Management LLC (11.35%), Soleus Capital Management L.P. (8.79%), Sands Capital Alternatives LLC (8.21%) and Divisadero Street Capital Management LP (2.18%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider and Mark Hopman. View institutional ownership trends. How do I buy shares of Beta Bionics? Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2025Today8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BBNX Previous SymbolNASDAQ:BBNX CIK1674632 WebN/A Phone(949) 427-7785FaxN/AEmployees294Year FoundedN/APrice Target and Rating Average Price Target for Beta Bionics$22.56 High Price Target$30.00 Low Price Target$16.00 Potential Upside/Downside+29.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio14.68 Quick Ratio13.79 Sales & Book Value Annual Sales$78.02 million Price / Sales9.72 Cash FlowN/A Price / Cash FlowN/A Book Value($5.72) per share Price / Book-3.05Miscellaneous Outstanding Shares43,470,000Free FloatN/AMarket Cap$758.55 million OptionableN/A BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BBNX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.